COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274586
Recruitment Status : Completed
First Posted : January 11, 2006
Last Update Posted : October 31, 2013
Information provided by:
Boehringer Ingelheim

Brief Summary:
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial among Taiwanese patients with previous TIA's or ischemic stroke.To monitor frequency and intensity of headaches and other safety parameters among Taiwanese patients with previous TIA's or ischemic stroke given Aggrenox using a titration scheme or not

Condition or disease Intervention/treatment Phase
Cerebrovascular Accident Drug: Aggrenox® modified release capsules Drug: Aggrenox® modified release capsules matching placebo Phase 3

Detailed Description:

The major objective of the study is to evaluate the tolerance of headache and safety in Taiwan Taiwanese patients who are receiving two different dosing regimens of Aggrenox and Aggrenox placebo. The first group will start with placebo on days 1-4, daily dose on days 5-14, and following by b.i.d treatment on 15-28 days. This group will also receive a matching placebo in the morning and one Aggrenox capsule in the evening before on days 5-14. It enables to reduce the perception of dipyridamole-associated headache. The second group will receive the placebo twice daily on days 1-4, and medication twice daily for the remaining course. The third group will receive the placebo twice daily for the whole course.

Study Hypothesis:


From a subject diary, asking for the most frequent side effects observed in the ESPS2 trial, the cumulative headache (intensity x frequency) per day based on the first three days of treatment period defines the primary endpoint.

I: H0: Median cumulative headache is equal for all treatment groups vs. HA: Median cumulative headache is not equal for all treatment groups

II: H0: Median cumulative headache of low dose regimen?Median cumulative headache of regular dose vs. HA: Median cumulative headache of low dose regimen < Median cumulative headache of regular dose


Compare Aggrenox full dose, reduced dose and placebo

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Tolerability of a Four Weeks Treatment With Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIAs or Ischemic Stroke
Study Start Date : September 2002
Actual Primary Completion Date : April 2003
Study Completion Date : April 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache

Primary Outcome Measures :
  1. Cumulated headache (intensity x frequency) over the first three days of treatment period

Secondary Outcome Measures :
  1. Proportion of (1) subjects drop out due to drug related AE and (2) experiencing grade 3 or 4 drug related headache during day 5-14, day 15-21 (reduced dose), day 5-11 (regular dose), day 7, day 28; as well as (3) Number of acetaminophen tablets used.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 20 years old or above.
  2. History of TIA or completed ischemic stroke
  3. Signed informed consent.
  4. Patient with score < 2 on modified Rankin's Classification of Neurological Status.

Exclusion Criteria:

  1. Patients with known or suspected prior intracranial haemorrhage or history of brain injury or brain tumor.
  2. Disorders related to syncope, drop attacks, congenital vascular malformation, aneurysm, angioma, or epilepsy, psychiatric disorders.
  3. Peptic ulcer or gastrointestinal bleeding within 6 months.
  4. History of hypersensitivity or intolerance to study drugs or aspirin.
  5. Experienced habitual headache (any form) within the past 3 months.
  6. History of dysphasia, dysphagia, dementia, or unconsciousness.
  7. Patients currently taking other medications known to cause headaches (e.g., nitrates).
  8. Patients with deteriorating angina, subvalvular aortic stenosis or hemodynamic liability (e.g., in conjunction with a recent myocardial infarction).
  9. Uncontrolled hypertension (SBP > 220 mmHg, DBP> 120 mmHg) or life-threatening disease.
  10. Any significant disorders, such as chronic renal failure (serum creatinine > 2.0 mg/dl), neoplasia.
  11. SGPT, SGOT value greater than 2 times of the upper normal limit.
  12. Insulin dependent diabetes mellitus or poorly controlled non-insulin dependent diabetes mellitus (AC sugar > 300 mg/dl).
  13. Use of other anticoagulants, such as anti-coagulated agents or NSAIDsS.
  14. History of alcohol and/or drug abuse.
  15. Having participated in other investigational drug study within 3 months prior to study entry.
  16. Pregnant or lactating women or women of childbearing potential whom are not practicing reliable birth control.
  17. The patients who take methylxanthine-containing drinks or foods (coffee, black tea, cola, energy drink, etc.) more than 4 cups of coffee or it's equivalents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00274586

Layout table for location information
Chang Gung Memorial Hospital
Taipei, Taiwan, 105
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Taiwan Ltd.

Layout table for additonal information Identifier: NCT00274586    
Other Study ID Numbers: 9.155
First Posted: January 11, 2006    Key Record Dates
Last Update Posted: October 31, 2013
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Aspirin, Dipyridamole Drug Combination
Platelet Aggregation Inhibitors